Board of Directors
Robert B. Cameron, M.D.
UCLA Medical School
Nicholas J. Vogelzang, M.D.
University of Chicago
M. Ann Abbe
Michael Harbut, M.D., M.P.H.
Royal Oak, MI
Roger G. Worthington, Esq.
Matthew Bergman, Esq.
St. Paul, Minnesota
Cary, North Carolina
Congressman Bruce F. Vento
Science Advisory Board
Harvey Pass, M.D., Chairman
Karmanos Cancer Institute
Victor Roggli, M.D.
Robert N. Taub, M.D.
Lary A. Robinson, M.D.
H. Lee Moffit Cancer Center
Steve Hahn, M.D.
University of Pennsylvania
Joseph R. Testa, Ph. D.
Fox Chase Cancer Center
Claire Verschraegen, M.D.
University of New Mexico
Eric Vallieres, M.D.
Swedish Cancer Institute
Dan Miller, M.D.
Raphael Bueno, M.D.
Harvard/Brigham and Women's
Hedy Lee Kindler, M.D.
University of Chicago
W. Roy Smythe, M.D.
Christopher E. Hahn
1609 Garden Street
Santa Barbara, CA 93101
tel (805) 560-8942
fax (805) 560-8962
Our mission is to eradicate mesothelioma as a life-ending disease.
October 20, 2004
Congressionally Directed Medical Research Programs (CDMRP)
The vision of the DoD's CDMRP is to "find and fund the best research
to eradicate diseases and support the warfighter for the benefit of the
American public." Their mission is to "provide hope by promoting
innovative research, recognizing untapped opportunities, creating partnerships,
and guarding the public trust."
The following overview of the CDMRP program comes from their website at
Genesis and Overview of the Congressionally Directed Medical Research Programs (CDMRP): The Congressionally Directed Medical Research Programs (CDMRP) originated
from a unique partnership among the public, Congress, and the Department
of Defense. Grassroots advocacy organizations provided much of the impetus
that led to a FY 92 appropriation of
$25 million targeted to funding research on the screening and diagnosis of breast
cancer among military women and dependents. In response to continuing
public requests led by the National Breast Cancer Coalition, Congress
appropriated an additional $210 million in FY93. Since that time, the
CDMRP has expanded to become second only to the National Cancer Institute
as a source of funding for breast cancer research. After noteworthy success
in managing the Breast Cancer Research Program, the CDMRP was tasked to
manage research programs in defense women's health, osteoporosis,
neurofibromatosis, prostate cancer, and ovarian cancer, tuberous sclerosis,
chronic myelogenous leukemia as well as other specified areas. The U.S.
Army Medical Research and Materiel Command (USAMRMC) been entrusted by
Congress to manage these special programs. However, The funds for the
Congressional Special Interest Medical Programs (CSI) are not in the President's
Budget; they are added to the DoD Budget by Congress.
- Total Congressional appropriations for research for the period of FY92-05
was almost $3.4 billion.
- Total number of grants/contracts awarded for the period of FY92-03 was 5,626
- Anticipated number of awards for FY04: 500
As detailed on their website (https://mrmc.detrick.army.mil/), the USAMRMC
is frequently directed by Congress to manage funding of research programs
with specific goals and end-points for health related issues relevant
to military personnel, military dependents, veterans, and the health of
the American public. These research programs ("Special Programs")
are generally concerned with topics relating to health-care delivery;
to detection, diagnosis, control or eradication of specified diseases,
conditions, or syndromes; or to other initiatives relevant to health needs.
Funding of these areas is dependent upon Congressional direction and availability
of funds. Guidance on the specific submission and evaluation process is
attached but may also be found at:http://www.usamraa.army.mil/pages/baa_paa/BAA_04-1_Rev.pdf ).